Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer

Author： O'Sullivan Coyne Geraldine Walsh Janice Kelly Catherine M

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.11, Iss.4, 2012-07, pp. : 643-650

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Eribulin mesylate for the treatment of breast cancer

By Cigler Tessa Vahdat Linda T

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 9, 2010-06 ,pp. : 1587-1593

Informa Healthcare

Access to resources Recommend Favorite

New Therapeutic Options for Chemotherapy-Resistant Metastatic Breast Cancer: The Epothilones

By Pronzato Paolo

Drugs, Vol. 68, Iss. 2, 2008-01 ,pp. : 139-146

Adis International

Access to resources Recommend Favorite

Therapeutic options for metastatic breast cancer

By Morris Patrick G McArthur Heather L Hudis Clifford A

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 967-981

Informa Healthcare

Access to resources Recommend Favorite

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration‐Resistant Prostate Cancer Treatment With Eribulin

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 7, 2015-08 ,pp. : 374-385

John Wiley & Sons Inc

Access to resources Recommend Favorite

Capecitabine is `a new effective oral treatment option' for patients with advanced and/or metastatic colorectal cancer

Inpharma, Vol. 1, Iss. 1234, 2000-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite